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http://dx.doi.org/10.1016/j.ccr.2014.03.021SUMMARYThe close vicinity of cancer cells undergoing epithelial-mesenchymal transition (EMT) and tumor-associated
macrophages (TAMs) at the invasive front of tumors suggests that these two cell type may mutually interact.
We show that mesenchymal-like breast cancer cells activate macrophages to a TAM-like phenotype by GM-
CSF. Reciprocally, CCL18 fromTAMs induces cancer cell EMT, forming a positive feedback loop, in coculture
systems and humanized mice. Inhibition of GM-CSF or CCL18 breaks this loop and reduces cancer metas-
tasis. High GM-CSF expression in breast cancer samples is associated with more CCL18+ macrophages,
cancer cell EMT, enhanced metastasis, and reduced patient survival. These findings suggest that a positive
feedback loop between GM-CSF and CCL18 is important in breast cancer metastasis.INTRODUCTION
It is well established that tumor microenvironment plays an
important role in cancer development and metastasis (Allavena
et al., 2008; Condeelis and Pollard, 2006). Tumor-associated
macrophages (TAMs), the most abundant immune-related stro-
mal cells in tumor microenvironment (Allavena et al., 2008), are
key orchestrators of tumor microenvironment, directly affecting
neoplastic cell growth, neoangiogenesis, and extracellular
matrix remodeling (Solinas et al., 2010). TAMs of breast cancer
often display an alternatively activated phenotype, promoting
tumor invasion and metastasis, and are associated with poor
prognosis in cancer patients (Chen et al., 2011; DeNardo et al.,Significance
Cancer cell epithelial-mesenchymal transition (EMT) and tum
increased metastasis and are frequently observed at the invas
tween cancer cells undergoing EMT and TAMs remains unkn
macrophages to a TAM-like phenotype via GM-CSF, suggesti
unappreciated source of TAMactivators. In turn, TAMs induce E
feedback loop. Furthermore, the interaction between cancer c
humanizedmousemodel of breast cancer, suggesting that the
apeutic target for cancer metastasis.2009). In addition, cancer cells can actively modulate nonmalig-
nant stromal cells, including macrophages (Pollard, 2004), in
tumor microenvironment to enhance cancer development and
metastasis (Joyce and Pollard, 2009). Cancer is a disease of het-
erogeneity and plasticity; however, it is not yet known whether
different kinds of cancer cells have different ability to modulate
tumor microenvironment.
Epithelial-mesenchymal transition (EMT) is a process whereby
cancer cells lose their epithelial properties to acquire a mesen-
chymal phenotype and become motile and invasive, which is
closely associated with metastasis (Thiery, 2002). EMT has
also been connected to induction of cancer stem cells (Mani
et al., 2008), drug resistance (Thiery et al., 2009), andor-associated macrophages (TAMs) are associated with
ive front of advanced tumors. However, the interaction be-
own. In this study, mesenchymal-like cancer cells activate
ng that mesenchymal-like cancer cells may be a previously
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Figure 1. Mesenchymal-like Breast Cancer Cells Activate Macrophages to a TAM-like Phenotype
(A–C) Macrophages were obtained by culture of monocytes in DMEM medium supplemented with 10% heat-inactivated human AB serum in the presence or
absence of 30% CM from indicated cell lines for 6 days. The primary TAMs were isolated from fresh human breast cancer tissue as positive controls.
(A) Fluorescent CD68/DAPI staining in macrophages. The scale bar represents 20 mm.
(B) Expression of CD206/HLA-DR in macrophages. The histograms are representatives of five independent experiments of macrophages from five different
donors. Numerical values denote the mean fluorescence intensity (MFI).
(C) Cytokine levels in the media of macrophages (mean ± SEM, n = 5 independent experiments; *p < 0.05, **p < 0.01, and ***p < 0.001 compared with control).
See also Figure S1.
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EMT may underlie many biological processes related to cancer
development. It has been reported that EMT of cancer cells is
frequently observed at the invasive front of advanced tumors
(Christofori, 2006; Francı´ et al., 2006), where TAMs are usually
found (Biswas andMantovani, 2010;Wyckoff et al., 2004). These
results suggest that cancer cells that undergo EMT may have a
selective advantage in modulating tumor microenvironment. In
this study, we investigated the interaction between cancer cells
with EMT and TAMs and explored the underlying mechanisms
that link these two metastasis-promoting phenomena.
RESULTS
Mesenchymal-like Breast Cancer Cells Activate
Macrophages to a TAM-like Phenotype
To investigate whether cancer cells with distinct epithelial or
mesenchymal-like phenotypes have different ability to activate
macrophages, we cultured freshly isolated human monocytes
in culture medium with 30% conditioned medium (CM) from six
breast cancer cell lines, including three typical epithelial-like606 Cancer Cell 25, 605–620, May 12, 2014 ª2014 Elsevier Inc.lines (MCF-7, BT-474, and T47D) and three mesenchymal-like
lines that express increased vimentin and decreased E-cadherin
(BT-549, MDA-MB-436, and MDA-MB-231) (Figure S1A avail-
able online), for 6 days to obtain macrophages. As a positive
control, we isolated primary TAMs from breast cancer tissue
and found that primary TAMs produced high amounts of protu-
mor cytokines (chemokine [C-C motif] ligand [CCL] 18, CCL17,
CCL22, and interleukin-10 [IL-10]) (Chen et al., 2011; Dangaj
et al., 2011; Mizukami et al., 2008) and exhibited a cluster of dif-
ferentiation (CD) 206high/human leukocyte antigen (HLA)-DRlow
phenotype that is associated with immunosuppression (Dangaj
et al., 2011; Kuang et al., 2007). Macrophages treated with CM
from mesenchymal-like lines, but not CM from epithelial-like
lines, became stretched and elongated (Figure 1A) and exhibited
a CD206high/HLA-DRlow phenotype (Figure 1B), similar to pri-
mary TAMs. Consistent with the changes in morphology and
surface markers, macrophages treated with CM from mesen-
chymal-like lines produced significantly more tumor-promoting
cytokines than untreated macrophages or those treated with
CM from epithelial lines (Figure 1C), indicating functional activa-
tion of TAMs. Moreover, the level of activation by CM from
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tion and CD206/HLA-DR expression, was comparable with
that of primary TAMs, suggesting that CM from mesenchymal-
like cancer cells is a strong macrophage activator.
To confirm whether the ability of cancer cells to activate TAMs
is determined by their mesenchymal state, we induced EMT of
MCF-7 cells with transforming growth factor b (TGF-b), tumor
necrosis factor a (TNF-a) or by mammosphere culture (Guttilla
et al., 2012) (Figure S1B). CM from MCF-7 cells that had
undergone EMT also induced both morphological and functional
TAM-like changes in macrophages, with CM from mammo-
sphere-cultured MCF-7 (MCF-7M) having the strongest effects
(Figures S1C–S1E). BT-474 cells in which EMT was induced
also showed similar effects (data not shown). Together, these
data indicate that mesenchymal-like cancer cells or cancer cells
that have undergone EMT can directly activate macrophages to
a TAM-like phenotype and may serve as a previously unappreci-
ated source of TAM activators as important as interleukin-4
(IL-4)-producing CD4+ T cells (DeNardo et al., 2009).
Granulocyte-Macrophage Colony-Stimulating Factor
Mediates the Activation of Macrophages by
Mesenchymal-like Breast Cancer Cells
To identify the cytokines secreted by mesenchymal-like cancer
cells that activate macrophages, the cytokine profiles of CM
from MCF-7, MCF-7 induced to undergo EMT by treatment of
TGF-b, TNF-a, and prolonged mammosphere culture, and
MDA-MB-231 cells were analyzed using RayBio Human Cyto-
kine Antibody Array. Five cytokines were significantly increased
in the CM of MCF-7 cells under EMT and MDA-MB-231 cells
compared with CM of MCF-7 cells, which are granulocyte-
macrophage colony-stimulating factor (GM-CSF), interleukin-8
(IL-8), CCL2, growth-regulated oncogene (GRO; includes
GROa, GROb, and GROg), and GROa (Figure 2A). ELISA further
confirmed the increases in GM-CSF, IL-8, CCL2, GROa, GROb,
and GROg in the CM of mesenchymal-like cells (Figure S2). We
then evaluated which of these cytokines is responsible for
activating TAMs. We found that only GM-CSF, but not IL-8,
CCL2, or GROs, significantly induced the production of TAM-
related cytokines to levels comparable with the CM from MDA-
MB-231 cells (Figure 2B). Addition of IL-8, CCL2, or GROs to
GM-CSF did not further enhance the activation (data not shown),
suggesting that GM-CSF alone is sufficient to activate
macrophages. Furthermore, the addition of a neutralizing anti-
GM-CSF antibody to the CM of MCF-7M, MDA-MB-231, and
MDA-MB-436 significantly suppressed the induction of the
TAM-related surface marker expression (Figure 2C) and cyto-
kines (Figure 2D), indicating that GM-CSF is necessary for
mesenchymal-like cancer cells to induce macrophage activation
to a TAM-like phenotype.
Tumor-Derived Lactate Abrogates the Proinflammatory
Cytokine Production from GM-CSF-Activated
Macrophages
It has been reported that GM-CSF can exhibit proinflammatory
or anti-inflammatory activity in different disease models, and it
has been hypothesized that conflicting roles of GM-CSF may
be due to the concomitant stimulation factors (Hamilton, 2002).
We compared the cytokine profiles of macrophages treatedwith interferon-g (IFN-g) (a standard activator of classically
activated macrophages), GM-CSF, or IL-4 (a standard activator
of alternatively activated macrophages). We found that GM-CSF
alone induced the production of both proinflammatory and anti-
inflammatory cytokines. As previously reported (Hamilton, 2008),
the addition of lipopolysaccharide (LPS) further increased the
production of proinflammatory cytokines (Figure S3A). However,
LPS is not a common factor found in tumor microenvironment.
We then explored the role of lactate, one of the most abundant
products of aerobic glycolysis and a widespread concomitant
factor in tumor microenvironment (Hirschhaeuser et al., 2011).
Breast cancer cell lines produced significantly more lactate
(4.8–15.6 mM) thanmacrophages or immortalized breast epithe-
lial cell lines (MCF-10A and HMLE) (0.8–1.7 mM) (Figure 3A). The
addition of 5 mM lactate abrogated the production of proinflam-
matory cytokines but did not inhibit or even promoted that of
anti-inflammatory cytokines from GM-CSF-activated macro-
phages (Figure 3B).
To further demonstrate the effect of tumor-derived lactate, we
treated macrophages with CM of MDA-MB-231 and found that
proinflammatory cytokines were significantly decreased, while
anti-inflammatory cytokines were significantly increased. The
suppression of proinflammatory cytokine production by 231
CM was completely reversed if the 231 cells were pretreated
by oxamic acid, an inhibitor of lactate dehydrogenase that
blocked the lactate production. The addition of exogenous
lactate in oxamic acid-pretreated 231 CM restored the suppres-
sion of the proinflammatory cytokines (Figure 3C; Figure S3B),
indicating that lactate is responsible for the skew of macro-
phages toward an anti-inflammatory phenotype.
Furthermore, we found that the higher the lactate level, the
lower the pH valuemeasured in the cell culturemedia (Figure 3A).
To investigate whether the lactate or the drop in pH level was
responsible for the suppression of proinflammatory cytokine
production, we adjusted the pH value of the oxamic acid-pre-
treated 231 CM to the level of untreated 231 CM by 1% hydro-
chloric acid (HCl) (Figure S3B). We found the acidification by
HCl did not suppress the production of proinflammatory cyto-
kines (Figure 3C), suggesting that it is the lactate, not the drop
in pH, that is accountable for the immunosuppressive effects
by CM of cancer cells.
GM-CSF-Activated Macrophages Induce EMT in Breast
Cancer Cells via CCL18
Previously, we have reported that TAMs can enhancemetastasis
of breast cancer cells (Chen et al., 2011; DeNardo et al., 2009),
which is often associated with EMT. Thus, we examined whether
activated macrophages can induce EMT of cancer cells. We
found thatMCF-7 cells,whencoculturedwithGM-CSF-activated
macrophages, changed from a rounded shape to an elongated
one, with loss of cell-cell contact, decrease of E-cadherin,
increase of vimentin, and enhancements of migration and inva-
siveness (Figures 4A and 4B; Figure S4A), suggesting that GM-
CSF-activatedmacrophages inducedEMTofbreastcancercells.
Further, anti-CCL18 neutralizing antibody inhibited EMT induced
by GM-CSF-activated macrophages, and CCL18 alone induced
EMT in MCF-7 (Figures 4A and 4B; Figure S4A), indicating that
CCL18 is the cytokine responsible for the EMT of breast cancer
cells induced by GM-CSF-activated macrophages.Cancer Cell 25, 605–620, May 12, 2014 ª2014 Elsevier Inc. 607
Figure 2. GM-CSF Mediates the Activation of Macrophages by Mesenchymal-like Breast Cancer Cells
(A) Cytokine array of the CM of MCF-7; MCF-7 induced to undergo EMT by treatment of TGF-b, TNF-a, and prolong mammosphere culture; and MDA-MB-231
cells. A table summarizing the relative signal intensity of indicated cytokines is presented in the lower left corner.
(B) Cytokines levels in the media of macrophages treated with indicated recombinant human cytokines at indicated concentrations (ng/ml) (mean ± SEM, n = 4
independent experiments of macrophages from four different donors).
(C) Expression of CD206/HLA-DR in macrophages treated with 30% indicated tumor-CM in the presence or absence of control IgG or a GM-CSF neutralizing
antibody. The histograms are representative of five independent experiments of macrophages from five different donors. Numerical values denote the MFI.
(D) Cytokine levels in the media of macrophages treated as in (C) (mean ± SEM, n = 5 independent experiments; *p < 0.05, **p < 0.01, and ***p < 0.001 compared
with macrophages treated with cancer cell CM alone; p values were obtained using two-tailed Student’s t tests).
See also Figure S2.
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cancer cells via the phosphatidylinositol 3-kinase (PI3K)/Akt/
glycogen synthase kinase 3b (GSK3b)/Snail signaling pathway
(Zhang et al., 2013). We also observed that CCL18 activated
PI3K/Akt pathways (data not shown). NF-kB is an important
transcription factor that links the activation of the PI3K/Akt
pathway with EMT (Julien et al., 2007). Thus, we explored the
role of NF-kB and found that CCL18 induced p65 nuclear trans-
location and enhanced NF-kB transcriptional activity through
membrane-associated phosphatidylinositol transfer protein 3
(PITPNM3) (Figure 4C; Figures S4B and S4C), indicating the acti-
vation of the NF-kBpathway. Inhibition of NF-kBby BAY-117082
(an IKK inhibitor), 4-methyl-N1-(3-phenyl-propyl)-benzene-
1,2-diamine (JSH-23) (an inhibitor of NF-kB nuclear transloca-
tion) or small interfering RNAs (siRNAs) to p65 reversed the
CCL18-induced EMT in MCF-7 cells (Figure 4D), suggesting
that CCL18 activates NF-kB pathway to induce EMT.
NF-kB is known to be important in EMT, and it also regulates
the expression of various cytokines, including GM-CSF, IL-8,
CCL2, and GRO (Barnes and Karin, 1997). We found that inhibi-
tion of NF-kB by pharmacological inhibitors or siRNA targeting
p65 not only led to decreased vimentin and increased E-cad-
herin in mesenchymal-like breast cancer cell lines (Figure 4D;
Figure S4D) but also inhibited their cytokine production in CM
(Figure 4E; Figure S4E), suggesting that high NF-kB activity
in cancer cells is not only essential to their mesenchymal proper-
ties but also important to the ability of secreting cytokines to
induce TAMs.
A Positive Feedback Loop between GM-CSF and CCL18
In Vitro
Becausemesenchymal-like cancer cells activate tumor-promot-
ing macrophages that can in turn induce EMT of cancer cells, we
investigated the possibility of a positive feedback loop between
TAMs and cancer cells with EMT. CCL18-treated MCF-7 cells
(MCF-7CCL18) displayed an elongated shape and mesenchymal
markers with increased GM-CSF in media. When these cells
were replated without CCL18, the cells gradually reversed to
their original round shape, with reexpression of E-cadherin and
loss of vimentin by day 5 (Figure 5B; Figure S5A). The GM-CSF
in the media also decreased after an initial increase within
48 hr (Figure 5A). However, coculture with macrophages main-
tained the mesenchymal state of MCF-7CCL18 cells, and the
levels of GM-CSF and CCL18 in media kept increasing through
day 5 (Figures 5A and 5B; Figure S5A). The cocultured macro-
phages became stretched and elongated and displayed a
CD206high/HLA-DRlow TAM-like phenotype (Figure S5B).
Furthermore, the addition of anti-GM-CSF or anti-CCL18
neutralizing antibodies led to regression of the mesenchymal
state of MCF-7CCL18 cells and TAM-like phenotype of macro-
phages, while decreasing the levels of both GM-CSF and
CCL18 in media (Figures 5A and 5B; Figures S5A and S5B), sug-
gesting mutually dependent increases of GM-CSF and CCL18 in
the coculture system of MCF-7CCL18 cells and macrophages.
On the other hand, GM-CSF-activated macrophages, when
replated without GM-CSF, slowly reversed to a CD206low/HLA-
DRhigh phenotype (Figure 5D), and the production of CCL18
decreased after the peak at day 4 (Figure 5C). Nevertheless,
coculture of GM-CSF-activated macrophages with MCF-7not only induced EMT of MCF-7 cells (Figure S5C) but also
maintained the TAM-like phenotype of the macrophages and
increased the levels of GM-CSF and CCL18 through day 20 (Fig-
ure 5C and 5D). The addition of anti-GM-CSF or anti-CCL18
neutralizing antibodies, but not control immunoglobulin G
(IgG), again led to the reversal of the mesenchymal state of
MCF-7 cells and the TAM-like phenotype of macrophages, as
well as decreasing GM-CSF and CCL18 in media (Figures 5C
and 5D; Figure S5C). Collectively, these data suggest that a
positive feedback loop between GM-CSF from mesenchymal-
like cancer cells and CCL18 from TAMs sustains or promotes
the mesenchymal state of cancer cells and the TAM-like pheno-
type of macrophages.
Furthermore, similar results were observed when we cocul-
tured MCF-7 cells with macrophages activated by CM of
MDA-MB-231, or cocultured macrophages with MDA-MB-231
cells or MCF-7 cells that were induced to EMT by TGF-b or
TNF-a (data not shown), corroborating the existence of a GM-
CSF-CCL18 positive feedback loop between TAMs and mesen-
chymal-like cancer cells.
The GM-CSF-CCL18 Loop Promotes EMT and
Metastasis in a Humanized Mouse Model of Breast
Cancer
It has been reported that chemokines released by human
macrophages are very different from those released by mouse
macrophages. Many of the chemokines upregulated in human
alternatively activated macrophages either lack murine ortho-
logs or are not upregulated in mice (Martinez et al., 2009).
CCL18, the key cytokine released by human macrophages to
promote metastasis (Chen et al., 2011), does not yet have a
mouse counterpart. Therefore, to study the interaction between
human macrophages and cancer cells in vivo, it is necessary to
use a humanized mouse model with human hematopoietic cells.
To establish such a model, nonobese diabetic (NOD)/severe
combined immunodeficiency (SCID) mice were treated with
anti-asialo-GM1 antibody to deplete host natural killer (NK) cells,
irradiated, transplanted with enriched CD34+ hematopoietic
stem cells (HSCs) isolated from fresh human umbilical cord
blood (CB) and injected with lentiviral vectors expressing human
CSF1 to improve human monocyte reconstitution. This model,
modified from a recent protocol (Wang et al., 2012), was
reported to increase the engraftment of human monocytes and
macrophages (Chen et al., 2009).
Engraftment of human HSCs into the mice resulted in the
detection of human CD45+ leukocytes, CD14+ monocytes and
macrophages, and CD19+ B cells in the peripheral blood
and xenografts of humanized mice. Few human CD3+ T cells
and CD56+ NK cells were detected (Figures S6A, S6B, and
S6E), which is consistent with previous reports (Ito et al., 2012;
Wang et al., 2012).
Consistent with the findings in vitro, injection of MCF-7CCL18
cells into the fat pads of humanized mice activated many
CCL18+ macrophages nearby, maintained the GM-CSF expres-
sion and EMT state of cancer cells (Figure 6A), and significantly
increased lung and liver metastasis (Figures 6B–6D), compared
with the injection of MCF-7CCL18 cells into the irradiated mice
without HSC transplantation or injection of MCF-7 cells without
CCL18 induction into the humanized mice. Anti-GM-CSFCancer Cell 25, 605–620, May 12, 2014 ª2014 Elsevier Inc. 609
Figure 3. Tumor-Derived Lactate Abrogates the Proinflammatory Cytokine Production from GM-CSF-Activated Macrophages
(A) The indicated cells were plated in a 24-well plate at a density of 23 105/ml. After 24 hr, lactate production and pH values were measured in the media (mean ±
SEM, n = 3; *p < 0.05 and **p < 0.01 compared with MCF10A; p values were obtained using two-tailed Student’s t tests).
(B) Macrophages were obtained by culture of monocytes in culture medium in the presence or absence of 500 U/ml IFN-g, 50 ng/ml GM-CSF, or 20 ng/ml IL-4 for
6 days. Afterward, macrophages were cultured in culture medium with or without 5 mM L-(+) lactic acid (lactate) for 24 hr. Cytokine levels in the media were
(legend continued on next page)
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cells adjacent to the tumor but also reversed the EMT state of
cancer cells and inhibited their metastasis. Furthermore, anti-
CCL18 antibody also decreased the expression of GM-CSF in
tumor cells, reversed the EMT state of cancer cells, and
inhibited metastasis (Figures 6A–6D). Neither GM-CSF nor
CCL18 blockade altered human leukocyte reconstitution, the
percentages of monocytes and macrophages (Figures S6A–
S6D), and primary tumor size (Figure 6E) in humanized mice.
These results indicate that GM-CSF from cancer cells and
CCL18 from TAMs form a positive feedback loop and promote
metastasis of cancer cells in vivo.
In addition, either anti-GM-CSF or anti-CCL18 antibody
prolonged the metastasis-free survival of humanized mice in-
jected with MCF-7CCL18 cells (Figure 6F), suggesting that the
GM-CSF-CCL18 loop could be a therapeutic target to inhibit
breast cancer metastasis. Similar results were observed in
humanized mice injected with MDA-MB-231, a mesenchymal
breast cancer cell line, or when GM-CSF was silenced in MCF-
7CCL18 cells or CCL18 was silenced in HSC-derived macro-
phages (data not shown) in humanized mice injected with
MCF-7CCL18 cells, substantiating the findings using MCF-
7CCL18 cells with neutralizing antibodies.
The GM-CSF-CCL18 Loop Is Associated with EMT,
Triple-Negative Subtype, Metastasis, and Poor
Prognosis in Breast Cancer Patients
To determine whether our findings are clinically relevant, we
examined 1,017 breast cancer cases from three independent
breast cancer centers for the expression of GM-CSF. We found
that GM-CSF was highly expressed in 293 (28.8%) cancer
samples, often observed at the invasive front, with no to
weak expression in normal or nonmalignant lesions of the
breast (Figure S7A). Double immunostaining of GM-CSF and
CCL18 showed significantly more stromal CCL18+ cells in
cancers with high GM-CSF expression than in cancers with
low GM-CSF expression (Figure 7A). The levels of GM-CSF
and CCL18 were also highly correlated in patients’ serum (Fig-
ure S7B). High GM-CSF expression was significantly correlated
with lymph node and distant metastasis, more advanced histo-
logical grade, triple-negative breast cancer subtype (Table S1).
Either GM-CSF or CCL18 was an independent prognostic
factor associated with poor prognosis (Figure 7B; Tables S2
and S3).
Furthermore, the cancer samples with high GM-CSF expres-
sion or more stromal CCL18+ cells nearby expressed sig-
nificantly less E-cadherin and more vimentin than the cancer
samples with less GM-CSF or CCL18 expression (Figures
S7C–S7E), an indication of EMT. More interestingly, the infiltra-
tion of CCL18+ macrophages was often observed at the invasivemeasured by ELISA (mean ± SEM, n = 4 independent experiments of macrophag
were obtained using two-tailed Student’s t tests).
(C) 231 cells were cultured in the presence or absence of 90 mM oxamic acid for 5
oxamic acid. In addition, the lactate or pH level in 231 cell CM treated with oxam
lactate or 1% HCl, respectively. Macrophages were obtained by culture of mon
6 days. The cytokine concentrations of the macrophages were measured afterw
different donors; *p < 0.05, **p < 0.01, and ***p < 0.001; p values were obtained
See also Figure S3.front of tumors, where cancer cells displayed more mesen-
chymal features and expressed high levels of GM-CSF
(Figure 7C). These data are consistent with the notion that
mesenchymal-like cancer cells secret more GM-CSF to activate
TAMs that produce CCL18 at the invasive front.
To further validate these findings, we searched the Oncomine
database for the prognostic value of GM-CSF and CCL18 in
human breast cancer. Four data sets showed a correlation
between GM-CSF expression and high-grade or triple-negative
subtype breast cancer, while one and four data sets showed
associations between CCL18 expression and high-grade breast
cancer and between CCL18 expression and triple-negative
subtype breast cancer, respectively. In addition, four and three
data sets confirmed that high levels of GM-CSF and of CCL18
are significantly correlated with poor prognosis in breast cancer
patients, respectively. Furthermore, four and two data sets
showed significantly inverse correlations between GM-CSF
and CCL18 expression and E-cadherin expression, respectively.
More important, in The Cancer Genome Atlas data set, with 593
breast cancer cases, GM-CSF was significantly correlated with
CCL18 in breast cancer samples (p < 0.0001) (Table 1). Collec-
tively, these data suggest that the GM-CSF-CCL18 loop plays
an important role in EMT and metastasis of human breast
cancer.
DISCUSSION
In this study, we show that cancer cells that have undergone
EMT secrete GM-CSF to activate macrophages to a TAM-like
phenotype. In turn, activated macrophages produce CCL18 to
induce EMT of cancer cells, forming a positive feedback loop.
This GM-CSF-CCL18 loop is essential to promoting the metas-
tasis of breast cancer cells and is associated with poor prog-
nosis in breast cancer patients.
EMT of cancer cells results in increased cell motility and is
associated withmetastasis. Our results indicate that cancer cells
that undergo EMT, often located at the invasive front of tumors,
have a superior function in activating macrophages to support
tumor expansion. Besides metastasis, EMT of cancer cells is
also linked with cancer stem cells, drug resistance, and immuno-
suppression (Kudo-Saito et al., 2009; Mani et al., 2008; Thiery
et al., 2009). We report here that the change of secretory cyto-
kine profile is also an important feature for cancer cells that un-
dergo EMT. We previously described that CCL18 is one of the
major cytokines released by TAMs and enhances breast cancer
cell metastasis (Chen et al., 2011). In line with these results,
CCL18 from activated macrophages induced EMT of breast
cancer cells through the activation of NF-kB. In addition, a panel
of inflammatory cytokines, including GM-CSF, CCL2, IL-8, and
GROs, were significantly induced as NF-kB target genes (Barneses from four different donors; *p < 0.05, **p < 0.01, and ***p < 0.001; p values
days. CMwere collected after the cells were cultured for another 24 hr without
ic acid were adjusted to the levels in untreated 231 cell CM by the addition of
ocytes in culture medium in the presence or absence of indicated 231 CM for
ard (mean ± SEM, n = 4 independent experiments of macrophages from four
using two-tailed Student’s t tests).
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Figure 4. GM-CSF-Activated Macrophages Induce EMT of Cancer Cells through CCL18
(A) Morphology and E-cadherin and vimentin expression of MCF-7 cells without or with the coculture of control macrophages (M4), GM-CSF-activated
macrophages alone or with control IgG, anti-CCL18 neutralizing antibody, or recombinant human CCL18. The scale bar represents 20 mm. GAPDH, glyceral-
dehyde 3-phosphate dehydrogenase.
(B) Migration and invasion assays of MCF-7 cells treated as in (A). The scale bar represents 200 mm (mean ± SEM, n = 3; **p < 0.01 and ***p < 0.001; p values were
obtained using two-tailed Student’s t tests).
(legend continued on next page)
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GM-CSF-CCL18 Loop Promotes Breast Cancer Metastasisand Karin, 1997) by CCL18. Among the cytokines induced during
EMT, GM-CSF is the one responsible for macrophage activation.
Other increased cytokines are also known to be important in
other aspects of tumor microenvironment, for example, CCL2
in recruiting monocytes (Qian et al., 2011), GROs in neutrophil
recruitment (Jinquan et al., 1995), and IL-8 in angiogenesis (Lin
et al., 2004). It is possible that the inflammatory factors induced
during EMT work together to provide a permissive environment
for tumor progression.
It has been reported that both breast cancer cells and macro-
phages comigrate and depend upon each other to be invasive
in vivo (Wyckoff et al., 2004). Our findingsmay extend knowledge
of interactions between cancer cells and macrophages by
showing that GM-CSF from cancer cells and CCL18 from
TAMs form a positive feedback loop to sustain or promote
EMT and metastasis of cancer cells. The levels of these two
cytokines are mutually dependent, such that neutralizing either
of them broke the vicious circle and suppressed breast cancer
metastasis in a humanized mouse model. These results,
together with the analysis of clinical samples, provide an expla-
nation for the colocalization of TAMs and cancer cells that have
undergone EMT at the invasive front of tumors.
Our data suggest a protumor role of GM-CSF in cancer. How-
ever, GM-CSF has been shown to elicit powerful immune
responses and is often used as an immune adjuvant to cancer
vaccines (Dranoff, 2002). However, the effect of exogenous
GM-CSF on cancer remains controversial. Some recent clinical
studies reported that GM-CSF as an adjuvant to different cancer
vaccines can lead to adverse outcome in terms of immune
response as well as relapse-free and overall survival (Faries
et al., 2009; Filipazzi et al., 2007; Slingluff et al., 2009). Careful
analysis suggested that GM-CSF may increase the vaccine-
induced immune response when administered repeatedly at
relatively low doses (range 40–80 mg for 1–5 days), whereas an
opposite effect was often reported at higher dosages of 100–
500 mg (Parmiani et al., 2007). Similar findings were also re-
ported in animal models (Serafini et al., 2004). Furthermore, it
has been consistently reported that endogenous GM-CSF
from cancer cells is capable of suppressing the immune
response (Bronte et al., 1999; Marigo et al., 2010; Tsuchiya
et al., 1988) and correlated with increased metastasis (Park
et al., 2007; Takeda et al., 1991). The analysis of our clinical sam-
ples as well as independent Oncomine data sets also showed
that GM-CSF is associated with poor prognosis in breast cancer
patients. We observed that LPS, a common factor of infectious
disease, skewed GM-CSF-activated macrophages to a proin-
flammatory phenotype, while lactate, one of the most abundant
tumor metabolites, changed GM-CSF-activated macrophages
to an anti-inflammatory phenotype. It is possible that long-
term proximal exposure to endogenous GM-CSF from cancer
cells together with tumor metabolites, unlike the short-term sys-(C) Confocal fluorescent microscopy of p65/DAPI staining in MCF-7 cells treated
PITPNM3. The scale bar represents 20 mm.
(D) Western blotting for E-cadherin and vimentin of CCL18-treated MCF-7 cells
siRNA or P65-siRNAs.
(E) The cytokine levels in the media of cells treated as in (D) (mean ± SEM, n = 3;
t tests).
See also Figure S4.temic use of low doses of GM-CSF in cancer vaccines, leads to
cancer progression.
Compared with immortalized breast epithelial cell lines, both
epithelial-like and mesenchymal-like breast cancer cell lines
produced significantly more lactate. Further, the addition of
5 mM lactate, which was equivalent to or lower than the amount
produced by both epithelial-like and mesenchymal-like breast
cancer cell lines (4.8–15.6 mM), abrogated the production of
proinflammatory cytokines but did not inhibit that of anti-inflam-
matory cytokines from GM-CSF-activated macrophages. These
results indicate that lactate produced by epithelial-like breast
cancer cells is sufficient to affect GM-CSF-activated macro-
phage. However, our data also demonstrated that GM-CSF
produced by epithelial-like breast cancer cell lines was signifi-
cantly less than that by mesenchymal-like breast cancer cells
and was insufficient to activate macrophages. Thus, both
increased lactate level and enhanced GM-CSF production are
needed for breast cancer cells to activate macrophages to an
anti-inflammatory phenotype.
Previous studies have identified the interaction between
cancer cells and macrophages, including the colony-stimulating
factor 1 (CSF-1)(macrophage colony-stimulating factor
[M-CSF])-epidermal growth factor (EGF) loop by using a rat
mammary cancer cell line (MTLn3) and mouse macrophages
(Goswami et al., 2005; Hernandez et al., 2009). When human
breast cancer line MDA-MB-231 was used in an in vivo mouse
xenograft model, the proportion of macrophages among the
invasive cells was only 6%, much less than the 25% observed
with rodent tumors (Patsialou et al., 2009). In addition, while
Iressa (an EGF receptor inhibitor) completely inhibited the EGF
or CSF-1-driven invasion in rodent tumor, it failed to do so in
the MDA-MB-231 xenografts (Patsialou et al., 2009). It is known
that the chemokine profiles of human and mouse macrophages
are very different. At least five chemokines that are upregulated
in human alternatively activated macrophages either lack mu-
rine orthologs or are not upregulated in mice (Martinez et al.,
2009). We find that GM-CSF is significantly induced in human
mesenchymal-like cancer cells and is responsible for the
macrophage activation, which then promotes the EMT of can-
cer cells to form the self-reinforcing loop. We also found that
CSF-1 is much lower than GM-CSF and is only mildly increased
in human mesenchymal-like cancer cells (data not shown).
Moreover, blocking the CSF1-EGF loop has no significant effect
on mesenchymal-like cancer cell-induced macrophage activa-
tion in vitro and metastasis of cancer cell in vivo (data not
shown). More important, our findings using human breast can-
cer cell lines and human macrophages were validated in a
humanized mouse model of breast cancer in vivo and further
corroborated in 1,017 clinical samples as well as Oncomine
data sets. Nevertheless, it is possible that GM-CSF plays an
indispensable role in initiating the positive feedback loop atwithout or with rhCCL20 or rhCCL18 together with siRNAs targeting GFP or
pretreated with DMSO, BAY-117082, or JSH-23 or pretransfected with GFP-
**p < 0.01 and ***p < 0.001; p values were obtained using two-tailed Student’s
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Figure 5. A Positive Feedback Loop between GM-CSF from Cancer Cells and CCL18 from Macrophages In Vitro
(A) Upper: schematic showing that MCF-7CCL18 cells were re-plated alone or cocultured with macrophages in transwell apparatus with 0.4 mm pore size with or
without control IgG, anti-GM-CSF, or anti-CCL18 neutralizing antibody for 5 days. Lower: GM-CSF and CCL18 levels in the indicated media were measured by
ELISA at indicated time points. All values are mean ± SEM, n = 4 independent experiments of macrophages from four different donors; *p < 0.05, **p < 0.01, and
***p < 0.001 compared with cells cultured alone; #p < 0.05, ##p < 0.01, and ###p < 0.001 compared with cells in the coculture systemwithout antibody addition at
the same time points (p values were obtained using two-tailed Student’s t tests).
(legend continued on next page)
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Cancer Cell
GM-CSF-CCL18 Loop Promotes Breast Cancer Metastasisthe early stage of metastasis, while other factors may be crucial
at later stages.
In summary, our study suggests an important role of the
positive feedback loop between cancer cells with EMT and
TAMs in cancer metastasis. The GM-CSF-CCL18 loop is essen-
tial for cancer cells to maintain or promote their mesenchymal
phenotype and could be a potential therapeutic target for cancer
metastasis.
EXPERIMENTAL PROCEDURES
Detailed procedures are provided in Supplemental Experimental Procedures.
Patients and Tissue Samples
Primary breast carcinomas were obtained from 759 patients at the Sun Yat-
Sen Memorial Hospital, Sun Yat-Sen University (Guangzhou, China), 145
patients at the First Affiliated Hospital, Shantou University Medical College
(Shantou, China), and 113 patients at Tianjin Medical University Cancer
Institute and Hospital (Tianjin, China). Normal breast tissue from 9 patients
undergoing breast reduction surgery and benign breast tissue samples from
23 patients with fibroadenoma and 17 patients with cystic fibrosis with or
without atypical epithelial hyperplasia were collected at Sun Yat-SenMemorial
Hospital. Additionally, serum levels of GM-CSF and CCL18 were measured in
peripheral blood samples from 151 patients with breast cancer before starting
therapy at Sun Yat-Sen Memorial Hospital. All samples were collected with
informed consent from patients, and all related procedures were performed
with the approval of the internal review and ethics boards of the indicated
hospitals.
Cell Culture and Treatment
MDA-MB-231, MDA-MB-436, BT-549, T47D, BT-474, and MCF-7 breast
cancer cells were obtained from American Type Culture Collection and grown
according to standard protocols. HMLE cells were kindly provided and
cultured as recommended by Dr. R.A. Weinberg (Whitehead Institute,
Cambridge, MA). When grown to 80% of confluence, cells were washed
with PBS, and fresh serum-free media were added. CM were harvested
24 hr later and filtered through a 0.22 mm filter. In some experiments, MCF-7
cells were treated with 5 ng/ml TGF-b, 10 ng/ml TNF-a, or 20 ng/ml CCL18
(PeproTech) for 2weeks or given prolongedmammosphere culture for 5weeks
as previously described (Guttilla et al., 2012). Afterward, cells were washed in
PBS and grown in adherent condition with cytokine/serum-free media, which
were harvested 24 hr later. To inhibit respective pathways, cells were incu-
bated with vehicle (DMSO), 5 mM BAY-117082, or 6 mM JSH-23 (Calbiochem)
for 1 hr at 37C prior to the experiments. To inhibit lactate production, cells
were treated with 90 mM oxamic acid (Sigma) for 5 days.
Primary Human TAM Isolation from Breast Cancer
TAMs were isolated from five fresh breast cancer samples as previously
described (Chen et al., 2011; Dangaj et al., 2011), with slight modifications.
Briefly, the tissues were minced into small (1 to 2 mm) pieces and digested
with 5% fetal bovine serum Dulbecco’s modified Eagle’s medium containing
2 mg/ml collagenase I and 2 mg/ml hyaluronidase (Sigma) at 37C for 2 hr.
The cells were sequentially filtered through 500 mm mesh, 100 mm, and
70 mm cell strainer. The cells were then centrifuged in a Beckman Allegra
X-15R centrifuge at 2,500 rpm for 20 min with 1 ml cell suspension above(B) Immunofluorescence analysis of E-cadherin (E-cad) and vimentin (Vim) in MCF
represents 20 mm.
(C) Upper: schematic showing that macrophages obtained by culture of monocyt
cocultured with untreated MCF-7 in the absence or presence of control IgG, anti-G
CCL18 levels in the indicated media were measured by ELISA at indicated time
phages from four different donors; *p < 0.05, **p < 0.01, and ***p < 0.001 compare
with cells in the coculture system without antibody addition at the same time po
(D) Surface marker detection by flow cytometry in GM-CSF-activated macrophag
experiments of macrophages from four different donors. Numerical values deno
See also Figure S5.5ml 45%Percoll (GEHealthcare) in themiddle and 5ml 60%Percoll at the bot-
tom in a 15 ml tube. Mononuclear cells were collected from the cell layer in the
interphase between 45% and 60% Percoll. CD14+ monocytes and macro-
phages were isolated by a magnetic-activated cell sorting using direct CD14
Isolation Kit (Miltenyi Biotec) according to the manufacturer’s instructions.
Hematopoietic Stem/Progenitor Cell Isolation
Fresh human CB was obtained from Sun Yat-Sen Memorial Hospital, accord-
ing to guidelines approved by the ethics boards and the Clinical Research
Committee at Sun Yat-Sen Memorial Hospital. The HSCs were isolated as
previously described (Holt et al., 2010). Briefly, CB mononuclear cells were
separated by density gradient of Ficoll-Hypaque. CD34+ HSCs were isolated
by using direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec). More
than 95% of CD34+ cells were positively selected after two rounds of enrich-
ment. The HSCs were transplanted within 24 hr after isolation.
Transplantation of CD34+ Cells and MCF-7 into NOD/SCID Mice
All animal work was conducted in accordance with a protocol approved by
the Institutional Animal Care and Use Committee at the medical college of
Sun Yat-Sen University. Female NOD/SCID mice (3 to 4 weeks old) were in-
jected intraperitoneally with 50 ml of anti-asialo-GM1 antibody (Wako) 24 hr
before HSC transplantation. The mice were subjected to 200 cGy total-
body irradiation 12 hr before being injected with 2 3 105 HSCs in 0.2 ml of
medium via the tail vein. After transplantation, treatment with anti-asialo-
GM1 antibody was repeated once every 4 days for 24 days. The mice
were injected with 0.1 ml of human M-CSF encoding lentiviral vectors at
titers ranging from 5 3 108 to 10 3 108 total TU/ml via the tail vein 1 week
after transplantation. At 8 weeks after HSC transplantation, 5 3 106 MCF-7
cells with indicated treatment were injected into the mammary fat pads of
the mice. To supplement estrogen for MCF-7 growth, each mouse was im-
planted with a 1.5 mg 17b-estradiol pellet (Innovative Research of America)
3 days before MCF-7 injection. For antibody treatment, mice were injected
with CCL18-specific neutralizing antibody (Catalog No. ab9849; abCAM)
and/or GM-CSF-specific neutralizing antibody (Catalog No. MAB215; R&D
Systems) via the tail vein at 10 mg/mouse twice weekly after the xenografts
became palpable (about 0.4 cm in diameter). Tumor growth was evaluated
by monitoring tumor volume (length 3 width2 3 0.5) every 3 days. The
whole-body metastasis burden of animals bearing xenografts that stably ex-
press luciferase was monitored using the IVIS Lumina Imaging System
(Xenogen) every 2 days as previously described (Oskarsson et al., 2011).
The animals were sacrificed when the xenografts reached 1.5 cm in diam-
eter. The plasma, tumor xenografts, lungs, and livers of the sacrificed mice
were harvested for further investigation. Sections (4 mm) of the harvested
organs were immunostained with antibody specific for human cytokeratin
(catalog no. ab756; abCAM), and total RNA was extracted for quantitative
reverse transcription polymerase chain reaction analysis of human hypoxan-
thine phosphoribosyltransferase (HPRT) mRNA expression.
Statistics
All statistical analysis was done using SPSS for Windows version 13.0 (SPSS).
Pearson’s correlation and regression analysis was performed to assess the
relationship between GM-CSF and CCL18 in the serum of patients and human
breast tissuemRNA expression data fromOncomine. Chi-square analysis was
applied to analyze the relationship between GM-CSF expression and clinico-
pathological status. Kaplan-Meier survival curves were plotted, and the log-
rank test was done. Groups of discrete variables were compared by means-7CCL18 cells alone or in the coculture system as described in (A). The scale bar
es in culture medium with 50 ng/ml GM-CSF for 6 days were re-plated alone or
M-CSF, or anti-CCL18 neutralizing antibody for 20 days. Lower: GM-CSF and
points. All values are mean ± SEM, n = 4 independent experiments of macro-
d with cells cultured alone; #p < 0.05, ##p < 0.01, and ###p < 0.001 compared
ints (p values were obtained using two-tailed Student’s t tests).
es as described in (C). The histograms are representative of four independent
te the MFI.
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Figure 6. The GM-CSF-CCL18 Loop Promotes EMT and Metastasis in a Humanized Mouse Model
MCF-7CCL18 orMCF-7 cells without CCL18 treatment were injected into themammary fat pads of NOD/SCIDmice with or without human hematopoietic stem cell
transplantation. Mice were injected with control IgG, anti-CCL18 neutralizing antibody, and/or anti-GM-CSF neutralizing antibody via the tail vein after the
xenografts became palpable.
(legend continued on next page)
Cancer Cell
GM-CSF-CCL18 Loop Promotes Breast Cancer Metastasis
616 Cancer Cell 25, 605–620, May 12, 2014 ª2014 Elsevier Inc.
Figure 7. The GM-CSF-CCL18 Loop Is Asso-
ciated with EMT and Metastasis in Breast
Cancer Patients
(A) Left: representative double IHC staining of GM-
CSF (red) and CCL18 (brown) in breast cancer
samples with low (upper panel; n = 724) or high
(lower panel; n = 293) GM-CSF expression. Right:
quantification of CCL18+ macrophages in human
breast cancer samples (mean ± SEM; ***p < 0.001; p
values were determined using Student’s t tests).
Scale bars represent 50 mm.
(B) Kaplan-Meier survival curve of breast cancer
patients with low (n = 724) and high (n = 293) GM-
CSF expression (p < 0.001 by log-rank test), with a
median follow-up period of 68 months. The number
of surviving patients stratified to the follow-up pe-
riods is indicated below the graph.
(C) Representative IHC staining for E-cadherin,
vimentin, GM-CSF, and CCL18 in the invasive front
and noninvasive front of serial sections from a
human breast cancer sample. The sample usedwas
derived from 1,017 breast cancer cases from three
independent breast cancer centers. Scale bars
represent 50 mm.
See also Tables S1–S3 and Figure S7.
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ance. All experiments for cell cultures were performed independently at least
three times and in triplicate each time. In all cases, p values < 0.05 were
considered statistically significant.(A) Upper: representative pictures of double immunohistochemical (IHC) staining o
the sections from indicated tumor xenografts. Arrows indicate CCL18+ cells. Inse
Lower: immunoreactive scores of E-cadherin (red) and vimentin (brown) and imm
within indicated xenografts (mean ± SEM, n = 8 for each group; ***p < 0.001 compa
humanized mice treated with control antibody; p values were determined using
(B) Representative bioluminescence imaging (upper panel) and lung and liver secti
cell metastasis (lower panel) in mice treated as in (A). Scale bars represent 50 mm
(C) Bioluminescence signal of lung and liver metastasis in mice with the indicate
p values were determined using Student’s t tests).
(D) Expression of human HPRT mRNA relative to mouse 18S rRNA in the lungs
nonhumanized mice (mean ± SEM, n = 8 for each group; **p < 0.01 and ***p < 0
(E) Tumor size during the course of each indicated treatment (arrow indicates be
(F) Kaplan-Meier analysis of metastasis-free survival in mice with the indicated trea
**p < 0.01 and ***p < 0.001; p values were determined using log-rank tests).
See also Figure S6.ACCESSION NUMBERS
The Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/)
accession number for the array data reported in this paper is GSE51938.f E-cadherin (red) and vimentin (brown) or GM-CSF (red) and CCL18 (brown) in
ts show CCL18+ cells at higher magnification. The scale bar represents 50 mm.
unoreactive scores of GM-CSF (red) and CCL18+ cell number counts (brown)
redwith cells in nonhumanizedmice; ##p < 0.01 comparedwithMCF-7CCL18 in
Kruskal-Wallis tests). Abs, antibodies.
ons immunostained with human cytokeratin antibody to indicate human cancer
.
d treatments (mean ± SEM, n = 8 for each group; **p < 0.01 and ***p < 0.001;
and livers of the tumor-bearing mice. Data were normalized to the group of
.001; p values were determined using Student’s t tests).
ginning of the treatment when tumor is palpable). Error bars show ±SEM.
tments. Metastasis was determined by bioluminescence (n = 8 for each group;
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Table 1. Correlation of CCL18 and GM-CSF Expression and Clinical Features in Breast Cancer in the Oncomine Online Database
Fold Change p Value Database (Case Number)
Upregulation of GM-CSF in Triple-Negative Breast Cancer
Triple-negative breast carcinoma versus others 2.174 <0.0001 TCGA Breast (593)
Triple-negative breast carcinoma versus others 2.600 0.013 Stickeler Breast (57)
Triple-negative breast carcinoma versus others 1.113 0.039 Waddell Breast (85)
Triple-negative breast carcinoma versus others 1.192 0.042 Kao Breast (327)
Upregulation of GM-CSF in High-Grade Breast Cancer
Grade III versus grades I and II 1.984 <0.0001 Loi Breast3 (77)
Grade III versus grades I and II 1.041 <0.0001 Curtis Breast (2136)
Grade III versus grades I and II 1.287 0.007 Gluck Breast (158)
Grade III versus grades I and II 1.926 0.015 Stickeler Breast (57)
Correlation of GM-CSF and Poor Prognosis in Breast Cancer
Metastasis at 5 years versus no metastasis at 5 years 1.422 0.002 Kao Breast (327)
Metastasis at 5 years versus no metastasis at 5 years 1.424 0.015 Bos Breast (204)
Metastasis at 5 years versus no metastasis at 5 years 1.077 0.001 Hatzis Breast (508)
Recurrence at 1 year versus no recurrence at 1 year 1.022 0.043 Vandevijver Breast (295)
Upregulation of CCL18 in Triple-Negative Breast Cancer
Triple-negative breast carcinoma versus others 2.053 <0.0001 TCGA Breast (593)
Triple-negative breast carcinoma versus others 2.695 0.006 Bild Breast (158)
Triple-negative breast carcinoma versus others 2.499 <0.0001 Bittner Breast (336)
Triple-negative breast carcinoma versus others 2.842 <0.0001 Chin Breast (118)
Upregulation of CCL18 in High-Grade Breast Cancer
Grade III versus grades I and II 3.771 0.002 Sorlie Breast (167)
Correlation of CCL18 and Poor Prognosis in Breast Cancer
Recurrence at 5 years versus no recurrence at 5 years 3.351 0.003 Ma Breast (60)
Dead at 5 years versus alive at 5 years 1.135 0.007 Vandevijver Breast (295)
Metastasis at 5 years versus no metastasis at 5 years 1.159 0.049 Hatzis Breast (508)
Correlation of GM-CSF and E-cadherin in Breast Cancer
Correlation of GM-CSF and E-cadherin in breast cancer 0.289 <0.0001 Hatzis Breast (508)
Correlation of GM-CSF and E-cadherin in breast cancer 0.116 0.004 TCGA Breast (593)
Correlation of GM-CSF and E-cadherin in breast cancer 0.183 0.001 Bittner Breast (336)
Correlation of GM-CSF and E-cadherin in breast cancer 0.112 0.043 Kao Breast (327)
Correlation of CCL18 and E-cadherin in Breast Cancer
Correlation of CCL18 and E-cadherin in breast cancer 0.090 0.043 Hatzis Breast (508)
Correlation of CCL18 and E-cadherin in breast cancer 0.238 0.015 TCGA Breast (593)
Correlation of CCL18 and GM-CSF in Breast Cancer
Correlation of CCL18 and GM-CSF in breast cancer 0.533 <0.0001 TCGA Breast (593)
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